$A

Dolsten Mikael sold $217K of A

Dolsten Mikael sold 1,600 shares of AGILENT TECHNOLOGIES, INC. (A) at $135.42 ($0.22M total) on 2026-05-29.

Original reporting
SEC EDGAR · Dolsten Mikael
Published Jun 2, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$A
Neutral
medium confidence
Mentioned
$A
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but this filing alone does not change the company’s fundamentals.

02

Market read

A director’s open-market sale is disclosed; absent other catalysts, expected impact is modest.

03

What to watch

No 10b5-1 plan is cited, but the sale size ($216.7K) is small relative to typical large-cap float, reducing interpretive power.

Relevance 6/10Novelty 6/10Timing: today’s SEC Form 4 disclosure (filed 2026-06-02)

Background

The article is an SEC EDGAR Form 4 insider transaction: a director reports an open-market sale of Agilent shares.

Company-level read

Ticker impact

$ANeutralMedium confidence
Context

Agilent director Dolsten Mikael sold 1,600 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; treat as low-signal unless part of a broader selling pattern.

Evidence & confidence

This is a routine Form 4 sale with no 10b5-1 plan and no accompanying fundamental news, so market reaction is typically muted.

Market effects

Minimal; this is company-specific insider activity with no sector-wide read-across.

None indicated.

None indicated.

Counterpoint

A single director sale can reflect diversification or liquidity needs rather than bearish fundamentals.

Key entities

  • Agilent Technologies, Inc.

    Subject of the SEC Form 4 insider sale disclosure.

  • Dolsten Mikael

    Director who sold 1,600 shares at $135.42 on 2026-05-29.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMedAI 9/10

Agilent completes acquisition of Proscia for $240 million

Agilent Technologies (NYSE:A) completed its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash, with up to $30 million in additional payments tied to future performance milestones. Proscia is now part of Agilent’s Life Sciences and Diagnostics Markets Group. The acquisition adds a recurring-revenue software business to Agilent’s pathology portfolio. Agilent generated $6.95 billion in revenue in fiscal year 2025.

$AHighAI 8/10

Software for examining tissue, trusted by 16 of the top 20 drug companies, now belongs to Agilent.

Agilent Technologies (A) completed the acquisition of Proscia, a digital pathology platform trusted by 16 of the top 20 drug companies. The deal expands Agilent’s pathology portfolio, adding a recurring-revenue software business and enhancing its AI-enabled pathology workflows. Proscia’s platform has FDA 510(k) clearance for primary diagnosis and supports clinical diagnostics, biopharma, and life-sciences research.

$AHighAI 9/10

Philadelphia's Proscia to Sell to Agilent for Up to $270M

Agilent Technologies (NYSE: A) agreed to acquire Proscia, a digital pathology software company, for up to $270M. The deal includes $240M upfront and $30M in performance-based payments. Proscia's software integrates AI tools and manages digital tissue images, serving over 4,000 labs and 16 top pharmaceutical firms. The acquisition aims to expand Agilent's presence in the $5B pathology market, combining its diagnostic instruments with Proscia's software.

$AHighAI 9/10

Philadelphia AI Cancer Diagnostics Firm Proscia Acquired for Up to $270M

Agilent Technologies (A) is acquiring Proscia, an AI cancer diagnostics firm, for up to $270M ($240M in cash, $30M in milestones). Proscia's software digitizes tissue samples for AI analysis, used by 4,000 labs and 16 top pharma companies. The deal expands Agilent's presence in digital pathology. Proscia will remain in Philadelphia, with the deal expected to close in early fiscal 2027.

$AHighAI 9/10

Agilent Agrees to Buy Proscia for $240M

Agilent Technologies agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. Proscia's trailing revenue exceeded $18M. The deal will integrate Proscia's digital pathology software into Agilent's business, expected to close in early fiscal 2027.

$BMBLHighAI 9/10

Deal Dispatch: Ithaca Holdings Buys Bumble for $1.3B, The Knot Acquires Zola, Character.ai Bankruptcy

Bumble (BMBL) agreed to a $1.3B all-cash acquisition by Ithaca Holdings, becoming privately held. IonQ will acquire Elisity in an all-stock deal up to $1.3B. Agilent (A) to buy Proscia for $240M. Workday (WDAY) acquiring C1.ai. Aurora Cannabis exploring alternatives to Curaleaf's bid. Character.ai filed for bankruptcy, Disney to pay $20M for IP. Getty Images plans Chapter 11, going private with Koch backing.